[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343210-105":59,"doc-detail-343210-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-common-druggable-signature-of-oncogenic-c-myc-mutant-kras-and-mutant-p53-reveals-functional-redundancy-and-competition-among-oncogenes-in-cancer","A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer","","The study addresses how redundancy and competition among major oncogenes reshape downstream programs and the ability to drive neoplasia. Using CRISPR-Cas9-mediated downregulation and RNAi screening across lung, colon, and pancreas cancer cell lines, it profiles proteomics and transcriptomics states with either one or all three oncogenes activated. A three-protein signature (RUVBL1, HSPA9, XPO1) emerges as efficiently targetable by novel drug combinations. The signature reflects redundant activation routes and promoter-level competition, supported by transcriptomics from cell lines and patient samples.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-common-druggable-signature-of-oncogenic-c-myc-mutant-kras-and-mutant-p53-reveals-functional-redundancy-and-competition-among-oncogenes-in-cancer/343210/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-common-druggable-signature-of-oncogenic-c-myc-mutant-kras-and-mutant-p53-reveals-functional-redundancy-and-competition-among-oncogenes-in-cancer/343210.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the paper investigate about MYC, KRAS, and TP53?","Question",{"text":112,"@type":113},"It evaluates whether redundancy and competition among these oncogenes affect their downstream molecular programs and their capacity to drive neoplasia.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the authors measure downstream effects of oncogene perturbation?",{"text":117,"@type":113},"They used CRISPR-Cas9-mediated downregulation and analyzed downstream proteomics and transcriptomics programs in a panel of cancer cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the reported druggable signature?",{"text":121,"@type":113},"The commonly activated molecular programs yield a signature of three proteins: RUVBL1, HSPA9, and XPO1, which can be targeted by novel drug combinations in the studied cancer types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343210,1790786863,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nA common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer  \nMaria Grześ1, Akanksha Jaiswar 1, Marcin Grochowski 1, Weronika Wojtyś1, Wojciech Kaźmierczak2, Tomasz Olesiński2, Małgorzata Lenarcik2, Magdalena Nowak-Niezgoda3, Małgorzata Kołos3, Giulia Canarutto 4, Silvano Piazza 4, Jacek R. Wiśniewski5 and Dawid Walerych 1 ✉  \n© The Author(s) 2024  \n\n| | The major driver oncogenes MYC, mutant KRAS, and mutant TP53 often coexist and cooperate to promote human neoplasia, which results in anticancer therapeutic opportunities within their downstream molecular programs. However, little research has been conducted on whether redundancy and competition among oncogenes affect their programs and ability to drive neoplasia. By CRISPR‒Cas9-mediated downregulation we evaluated the downstream proteomics and transcriptomics programs of MYC, mutant KRAS, and mutant TP53 in a panel of cell lines with either one or three of these oncogenes activated, in cancers of the lung, colon and pancreas. Using RNAi screening of the commonly activated molecular programs, we found a signature of three proteins RUVBL1, HSPA9, and XPO1, which could be efﬁciently targeted by novel drug combinations in the studied cancer types.\u003Cbr>Interestingly, the signature was controlled by the oncoproteins in a redundant or competitive manner rather than by cooperation. Each oncoprotein individually upregulated the target genes, while upon oncogene co-expression each target was controlled preferably by a dominant oncoprotein which reduced the inﬂuence of the others. This interplay was mediated by redundant routes of target gene activation-as in the case of mutant KRAS signaling to c-Jun/GLI2 transcription factors bypassing c-Myc activation, and by competition - as in the case of mutant p53 and c-Myc competing for binding to target promoters. The global transcriptomics data from the cell lines and patient samples indicate that the redundancy and competition of oncogenic programs are broad phenomena, that may constitute even a majority of the genes dependent on oncoproteins, as shown for mutant p53 in colon and lung cancer cell lines. Nevertheless, we demonstrated that redundant oncogene programs harbor targets for efﬁcient | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | anticancer drug combinations, bypassing the limitations for direct oncoprotein inhibition. |  |\n|  |  |  |\n|  |  |  |\n|  | Cell Death and Disease (2024)15:638; [https://doi.org/10.1038/s41419-024-06965-3](https://doi.org/10.1038/s41419-024-06965-3) |  |\n|  |  |  |\n\nINTRODUCTION  \nThe most deadly cancer types exhibit frequent upregulation ofc-Myc and mutations in KRAS and TP53 [1] . However, the understanding of the intersections of molecular programs driven by these universal oncogenes is limited, and has not produced standard therapeutic solutions for cancer treatment [2] .  \nThe most frequently altered gene on average in human neoplasia is TP53, which encodes the essential tumor suppressor p53 . Upon acquisition of missense mutations, TP53 not only loses its suppressive properties but often acquires oncogenic gain-offunction [3, 4] . Nevertheless, none of the drugs targeting mutant p53 directly are yet available as standard therapies [5], many are known for lack of direct efﬁciency and off-target effects [6] .  \nKRAS missense mutations, which occur at high rates in pancreatic (more than 85% of cases), colorectal (~40%) and nonsmall cell lung (~30%) cancers, lead to persistent activation of the protein’s GTPase activity and downstream signaling through the  \nPI3K-AKT-mTOR, MAP kinase and RAL pathways, among others [7] . The FDA-approved KRAS inhibitors, sotorasib and adagrasib, targeting the G12C mutation, suffer fr","cbCaifyQsuV5Q7yj","https://ap.wps.com/l/cbCaifyQsuV5Q7yj","pdf",5695638,14,"English","# Introduction\n## Oncogene co-occurrence and therapeutic implications\n## Experimental strategy and downstream program profiling\n## Functional redundancy and competition mechanisms\n## Targetable protein signature and drug-combination rationale","[{\"question\":\"What question does the paper investigate about MYC, KRAS, and TP53?\",\"answer\":\"It evaluates whether redundancy and competition among these oncogenes affect their downstream molecular programs and their capacity to drive neoplasia.\"},{\"question\":\"How did the authors measure downstream effects of oncogene perturbation?\",\"answer\":\"They used CRISPR-Cas9-mediated downregulation and analyzed downstream proteomics and transcriptomics programs in a panel of cancer cell lines.\"},{\"question\":\"What is the reported druggable signature?\",\"answer\":\"The commonly activated molecular programs yield a signature of three proteins: RUVBL1, HSPA9, and XPO1, which can be targeted by novel drug combinations in the studied cancer types.\"}]","A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer | PDF",1790050300,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07032649dd27c9c08bb852dec0e9e9d7.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1754ec03db6391bc1c516ae813526ea.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cde515ab2c7d90a03d5d113cc65d2284.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac34a73049e6f53f518d7fd5e903caf8.webp",980,1301]